Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

IVETTE CHRISTINE ESPINOSA-FERNANDEZ

Allopathic & Osteopathic Physicians General Practice

NPI
1295771665
CMS profile
571394
Location
SOUTH MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$11.61

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $11.61 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Ortho Dermatologics, a division of Bausch Health US, LLC $11.61 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

IVETTE CHRISTINE ESPINOSA-FERNANDEZ

NPI 1295771665 · CMS profile ID 571394

Allopathic & Osteopathic Physicians / General Practice

SOUTH MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295771665?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
IVETTE CHRISTINE ESPINOSA-FERNANDEZ, NPI 1295771665, CMS profile ID 571394. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295771665?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). IVETTE CHRISTINE ESPINOSA-FERNANDEZ, NPI 1295771665, CMS profile ID 571394. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295771665?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
IVETTE CHRISTINE ESPINOSA-FERNANDEZ, NPI 1295771665, CMS profile ID 571394, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1295771665?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $11.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ortho Dermatologics, a division of Bausch Health US, LLC $11.6106/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684576135 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $11.61 1
PY2024 $14.71 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $279,724.89 30
PY2024 Principal investigator $970,618.20 67
PY2023 Principal investigator $595,898.17 34
PY2022 Principal investigator $177,617.64 13
PY2021 Principal investigator $41,579.50 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $26,991.36 12/11/2024 Non-covered Recipient Entity
REVIVAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125500494
Principal investigator 1 ModernaTX, Inc. $2,000.00 12/06/2024 Non-covered Recipient Entity
Revival Research Corporation - ClinEdge - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147165181
Principal investigator 1 ModernaTX, Inc. $45,972.46 12/06/2024 Non-covered Recipient Entity
Revival Research Corporation - ClinEdge - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147165189
Principal investigator 1 ModernaTX, Inc. $1,800.00 12/02/2024 Non-covered Recipient Entity
Revival Research Corporation - ClinEdge - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147165185
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $33,958.98 12/02/2024 Non-covered Recipient Entity
REVIVAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125500026
Principal investigator 1 ABBVIE INC. $845.40 11/06/2024 Non-covered Recipient Entity
REVIVAL RESEARCH CORPORATION
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100752691
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $57,216.72 11/01/2024 Non-covered Recipient Entity
REVIVAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125499039
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,000.00 10/25/2024 Non-covered Recipient Entity
REVIVAL RESEARCH
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 1125498815
Principal investigator 1 ModernaTX, Inc. $4,034.97 10/18/2024 Non-covered Recipient Entity
Revival Research Corporation - Michigan - ClinEdge - PPDS
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147165177
Principal investigator 1 Abbott Laboratories $52.50 09/30/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166890
Principal investigator 1 Abbott Laboratories $18.00 09/30/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166892
Principal investigator 1 Abbott Laboratories $8.00 09/30/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166894
Principal investigator 1 Abbott Laboratories $36.00 09/30/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166896
Principal investigator 1 Abbott Laboratories $114.20 09/30/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166898
Principal investigator 1 Abbott Laboratories $47.60 09/30/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166900
Principal investigator 1 Abbott Laboratories $140.80 09/30/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166902
Principal investigator 1 Abbott Laboratories $17.70 09/30/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166904
Principal investigator 1 Abbott Laboratories $17.70 09/30/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166906
Principal investigator 1 Abbott Laboratories $464.00 09/30/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166908
Principal investigator 1 Abbott Laboratories $2,284.36 09/30/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166910
Principal investigator 1 Abbott Laboratories $1,102.60 09/30/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166912
Principal investigator 1 Abbott Laboratories $10,374.00 09/30/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166914
Principal investigator 1 ModernaTX, Inc. $29,434.45 09/18/2024 Non-covered Recipient Entity
Revival Research Corporation - Michigan - ClinEdge - PPDS
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147165165
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $57,154.68 09/11/2024 Non-covered Recipient Entity
REVIVAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125497301
Principal investigator 1 ModernaTX, Inc. $1,500.00 08/23/2024 Non-covered Recipient Entity
Revival Research Corporation - ClinEdge - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147165157
Principal investigator 1 ModernaTX, Inc. $25,998.59 08/23/2024 Non-covered Recipient Entity
Revival Research Corporation - ClinEdge - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147165161
Principal investigator 1 ModernaTX, Inc. $1,399.43 08/16/2024 Non-covered Recipient Entity
Revival Research Corporation - Michigan - ClinEdge - PPDS
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147165141
Principal investigator 1 Galderma Laboratories, L.P. $213.54 08/08/2024 Non-covered Recipient Entity
REVIVAL RESEARCH CORPORATION
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab No dispute reported 06/30/2026 1156049215
Principal investigator 1 ABBVIE INC. $4,445.70 08/01/2024 Non-covered Recipient Entity
REVIVAL RESEARCH CORPORATION
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100733122
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $88,858.44 08/01/2024 Non-covered Recipient Entity
REVIVAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125494835
Principal investigator 1 ModernaTX, Inc. $3,498.57 07/24/2024 Non-covered Recipient Entity
Revival Research Corporation - Michigan - ClinEdge - PPDS
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147164924
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $53,679.12 07/10/2024 Non-covered Recipient Entity
REVIVAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125493832
Principal investigator 1 ModernaTX, Inc. $13,994.28 06/20/2024 Non-covered Recipient Entity
Revival Research Corporation - Michigan - ClinEdge - PPDS
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147164920
Principal investigator 1 ModernaTX, Inc. $3,605.85 05/17/2024 Non-covered Recipient Entity
Revival Research Corporation - Michigan - ClinEdge - PPDS
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147164912
Principal investigator 1 Chiesi USA, Inc. $2,689.00 05/10/2024 Non-covered Recipient Entity
REVIVAL RESEARCH CORPORATION
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148219772
Principal investigator 1 ABBVIE INC. $563.60 05/08/2024 Non-covered Recipient Entity
REVIVAL RESEARCH CORPORATION
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100716404
Principal investigator 1 Abbott Laboratories $47.60 05/08/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166888
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $51,602.76 04/26/2024 Non-covered Recipient Entity
REVIVAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125490493
Principal investigator 1 Abbott Laboratories $310.50 04/24/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166868
Principal investigator 1 Abbott Laboratories $17,157.00 04/24/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166870
Principal investigator 1 Abbott Laboratories $1,757.20 04/24/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166872
Principal investigator 1 Abbott Laboratories $1,318.24 04/24/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166874
Principal investigator 1 Abbott Laboratories $36.00 04/24/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166876
Principal investigator 1 Abbott Laboratories $52.50 04/24/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166878
Principal investigator 1 Abbott Laboratories $8.00 04/24/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166880
Principal investigator 1 Abbott Laboratories $18.00 04/24/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166882
Principal investigator 1 Abbott Laboratories $47.60 04/24/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166884
Principal investigator 1 Abbott Laboratories $140.80 04/24/2024 Non-covered Recipient Entity
Revival Research Corporation
Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study using Venous and/or Capillary Reference No dispute reported 06/30/2026 1146166886
Principal investigator 1 ModernaTX, Inc. $19,960.29 04/10/2024 Non-covered Recipient Entity
Revival Research Corporation - Michigan - ClinEdge - PPDS
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147164860
Principal investigator 1 ABBVIE INC. $2,950.80 04/04/2024 Non-covered Recipient Entity
REVIVAL RESEARCH CORPORATION
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100711946
Principal investigator 1 ModernaTX, Inc. $17,702.14 03/27/2024 Non-covered Recipient Entity
Revival Research Corporation - ClinEdge - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147164888
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $30,645.12 03/27/2024 Non-covered Recipient Entity
REVIVAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125488901
Principal investigator 1 ModernaTX, Inc. $20,506.27 03/15/2024 Non-covered Recipient Entity
Revival Research Corporation - Michigan - ClinEdge - PPDS
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147164892
Principal investigator 1 Chiesi USA, Inc. $735.00 03/08/2024 Non-covered Recipient Entity
REVIVAL RESEARCH CORPORATION
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148217023
Principal investigator 1 ABBVIE INC. $1,127.20 03/07/2024 Non-covered Recipient Entity
REVIVAL RESEARCH CORPORATION
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100707322
Principal investigator 1 ModernaTX, Inc. $95,417.77 03/01/2024 Non-covered Recipient Entity
Revival Research Corporation - ClinEdge - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147164880
Principal investigator 1 ModernaTX, Inc. $91,404.11 03/01/2024 Non-covered Recipient Entity
Revival Research Corporation - ClinEdge - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147164884
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,491.72 02/28/2024 Non-covered Recipient Entity
REVIVAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125487074
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,755.00 02/23/2024 Non-covered Recipient Entity
REVIVAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125486824
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 02/23/2024 Non-covered Recipient Entity
REVIVAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125486828
Principal investigator 1 ModernaTX, Inc. $19,591.99 02/16/2024 Non-covered Recipient Entity
Revival Research Corporation - Michigan - ClinEdge - PPDS
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147164833
Principal investigator 1 Chiesi USA, Inc. $1,834.00 02/14/2024 Non-covered Recipient Entity
REVIVAL RESEARCH CORPORATION
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148216052
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,151.58 02/09/2024 Non-covered Recipient Entity
REVIVAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125486133
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24,204.84 02/02/2024 Non-covered Recipient Entity
REVIVAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125484823
Principal investigator 1 ABBVIE INC. $3,771.40 02/01/2024 Non-covered Recipient Entity
REVIVAL RESEARCH CORPORATION
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1100702172
Principal investigator 1 ModernaTX, Inc. $45,745.17 01/17/2024 Non-covered Recipient Entity
Revival Research Corporation - Michigan - ClinEdge - PPDS
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147164813
Principal investigator 1 Chiesi USA, Inc. $795.00 01/10/2024 Non-covered Recipient Entity
REVIVAL RESEARCH CORPORATION
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148214175